Trial reportAnnals of nuclear medicine2025
Molecular imaging using
Trial report in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06241807 (A Phase II Trial of Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB Non-Small Cell Lung Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Trial of Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB Non-Small Cell Lung Cancer
Who cites it
1 citing paper in PubMed.
- A narrative review of pathologic response in non-small cell lung cancer: challenges, implications, and future directions.Translational lung cancer research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aims to predict the pathological response of patients with non-small cell lung cancer (NSCLC) in prospective trials of neoadjuvant camrelizumab combined with chemotherapy by integrating the clinical characteristics, PET-associated parameters, and hematological indicators.
methodsA prospective analysis was conducted among 24 patients undergoing surgery after neoadjuvant camrelizumab plus chemotherapy.
resultsMajor pathological response (MPR) and pathological complete response (pCR) were achieved in 45.8% (11/24) and 33.3% (8/24) of patients. Before treatment, patients who achieved a pCR had significantly greater SUVmax values (p = 0.011) than non-pCR patients. After treatment, the MPR group exhibited significantly lower SUVmax values than the non-MPR group (p = 0.048). The rate of change in the SUVmax (ΔSUVmax%) differed significantly between the pCR and non-pCR groups (p = 0.019) and between the MPR and non-MPR groups (p = 0.013). After NAT, the lymph nodes' SUVmax in the ypN0 group was significantly lower than that in the ypN + group (p = 0.032). ROC analysis indicated that pre-NAT SUVmax and ΔSUVmax% best distinguished pCR and MPR patients, respectively, with AUCs of 0.82 (p = 0.012) and 0.80 (p = 0.014).
conclusionPre-NAT SUVmax, and ΔSUVmax% are promising biomarkers for predicting pathological response to neoadjuvant camrelizumab and chemotherapy. CLINICALTRIALS: GOV ID: NCT06241807.
Indexed as
Identifiers
40348946What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.